<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HD2B3E965C81347CDBA36D269B1794ABC" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 1839 IH: Combating Illicit Xylazine Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-03-28</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1839</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230328">March 28, 2023</action-date><action-desc><sponsor name-id="P000613">Mr. Panetta</sponsor> (for himself, <cosponsor name-id="P000048">Mr. Pfluger</cosponsor>, <cosponsor name-id="B001257">Mr. Bilirakis</cosponsor>, <cosponsor name-id="B001297">Mr. Buck</cosponsor>, <cosponsor name-id="P000614">Mr. Pappas</cosponsor>, <cosponsor name-id="B001298">Mr. Bacon</cosponsor>, <cosponsor name-id="L000564">Mr. Lamborn</cosponsor>, <cosponsor name-id="V000136">Mr. Vasquez</cosponsor>, <cosponsor name-id="T000460">Mr. Thompson of California</cosponsor>, and <cosponsor name-id="H001085">Ms. Houlahan</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HJU00">the Judiciary</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To prohibit certain uses of xylazine, and for other purposes.</official-title></form><legis-body id="H823E51AB18E647F1BEF13A14A8366698" style="OLC"> 
<section id="HD4E73D20044C4170B1B77E7FFF8D3F25" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Combating Illicit Xylazine Act</short-title></quote>.</text></section> <section id="HCA6597CD12804D0A90C551CCDF89CF76"><enum>2.</enum><header>Findings</header><text display-inline="no-display-inline">Congress finds the following:</text>
<paragraph id="HD06A47B078AE4685AA7F6438420BBC35"><enum>(1)</enum><text display-inline="yes-display-inline">Illicit xylazine presents an urgent threat to public health and safety.</text></paragraph> <paragraph id="HE15E0BA4E1154970A9E905AB8CFA13B6"><enum>(2)</enum><text>The proliferation of xylazine as an additive to illicit drugs such as fentanyl and other narcotics threatens to exacerbate the opioid public health emergency.</text></paragraph>
<paragraph id="HD2E58EFBC9D94D4790A43D72B44BFC9A"><enum>(3)</enum><text>There is currently no drug approved by the Food and Drug Administration to reverse the effects of xylazine in humans.</text></paragraph> <paragraph id="H8B22ADFD37DD4BE1AC095D39F83FBEF4"><enum>(4)</enum><text>The physical effects of use of xylazine in humans can include depressed breathing and heart rate, unconsciousness, and necrosis, sometimes leading to amputation or other permanent physical health consequences.</text></paragraph>
<paragraph id="H6DDFACA5F2E5452C931B8237EB58BBA1"><enum>(5)</enum><text>The spread of illicit xylazine use has followed geographic patterns seen in the spread of recreational fentanyl use, with proliferation beginning in the Northeastern United States and later spreading south and west.</text></paragraph> <paragraph id="H3EA116E2081E4730904994D07E88C8D8"><enum>(6)</enum><text>Prompt action to control illicit xylazine will help limit further proliferation of illicit xylazine, saving countless lives.</text></paragraph></section>
<section id="H076C1916052A45BB87ED7FF17F2F9FD4"><enum>3.</enum><header>Definitions</header>
<subsection commented="no" display-inline="no-display-inline" id="HFF7F64E13D2148B0A4C6AC222D757877"><enum>(a)</enum><header display-inline="yes-display-inline">In general</header><text>In this Act, the term <term>xylazine</term> has the meaning given the term in paragraph (60) of section 102 of the Controlled Substances Act, as added by subsection (b) of this section.</text></subsection> <subsection commented="no" display-inline="no-display-inline" id="HB1C23BACC5A94B34BB8408A31C359F7F"><enum>(b)</enum><header>Controlled Substances Act</header><text display-inline="yes-display-inline">Section 102 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/802">21 U.S.C. 802</external-xref>) is amended—</text>
<paragraph commented="no" display-inline="no-display-inline" id="HD5FF130F3ADE435E9CA886BBC84E1AAB"><enum>(1)</enum><text display-inline="yes-display-inline">by redesignating the second paragraph (57) (relating to serious drug felony) and paragraph (58) as paragraphs (58) and (59), respectively; and</text></paragraph> <paragraph commented="no" display-inline="no-display-inline" id="H2ECFFDED9FD34DE0AAF2EA2765264FDF"><enum>(2)</enum><text display-inline="yes-display-inline">by adding at the end the following:</text>
<quoted-block style="OLC" display-inline="no-display-inline" id="H4EBA07C55D2742B4839D6265A69EF0F5">
<paragraph commented="no" display-inline="no-display-inline" id="H424679F9A48D4110886EBA974216AF01" indent="up1"><enum>(60)</enum><text>The term <term>xylazine</term> means any of the following substances, including their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:</text> <subparagraph id="HEC767809C0AC4CB0975C875ED67BF1DC" commented="no"><enum>(A)</enum><text>Xylazine.</text></subparagraph>
<subparagraph id="H8C78AA43162243C09DBC07C16C63FE84" commented="no"><enum>(B)</enum><text>Xylazine-M (2,6Mich dimethylaniline).</text></subparagraph> <subparagraph id="H618BAC55DFA0424CA4E0928E0319FB76" commented="no"><enum>(C)</enum><text>Xylazine-M (N-thiourea-2,6-dimethylaniline).</text></subparagraph>
<subparagraph id="H17D243FFBA0B49DF996B8B5F1451A70D" commented="no"><enum>(D)</enum><text>Xylazine-M (sulfone-HO-) isomer 2.</text></subparagraph> <subparagraph id="H7E1C8958DE204FE68653DAF560FE2325" commented="no"><enum>(E)</enum><text>Xylazine-M (HO-2,6-dimethylaniline isomer 1).</text></subparagraph>
<subparagraph id="H1BEE22AD4C8947DBA070624CA0A5ED13" commented="no"><enum>(F)</enum><text>Xylazine-M (HO-2,6-dimethylaniline isomer 2).</text></subparagraph> <subparagraph id="H0C672DC6221646A1B75614D29F4889A3" commented="no"><enum>(G)</enum><text>Xylazine M (oxo-).</text></subparagraph>
<subparagraph id="H4E8A8BB977CF4C5BB8F22F2937358DC6" commented="no"><enum>(H)</enum><text>Xylazine-M (HO-) isomer 1.</text></subparagraph> <subparagraph id="H53B93A967C1F450D9AADB1A88813835C" commented="no"><enum>(I)</enum><text>Xylazine-M (HO-) isomer 1 glucuronide.</text></subparagraph>
<subparagraph id="HDB6E2AEC1F484144999E167E47FE77EE" commented="no"><enum>(J)</enum><text>Xylazine-M (HO-) isomer 2.</text></subparagraph> <subparagraph id="HECF2C99CBEA2443D8F25BC6B3DB4DF87" commented="no"><enum>(K)</enum><text>Xylazine-M (HO-) isomer 2 glucuronide.</text></subparagraph>
<subparagraph id="HEBA3087B6291459782AF0D9462108066" commented="no"><enum>(L)</enum><text>Xylazine-M (HO-oxo-) isomer 1.</text></subparagraph> <subparagraph id="H91572F2E03CC4D50A91A0B612C9303FE" commented="no"><enum>(M)</enum><text>Xylazine-M (HO-oxo-) isomer 1 glucuronide.</text></subparagraph>
<subparagraph id="H4162FAC17A7E4717B2DE352C04F09688" commented="no"><enum>(N)</enum><text>Xylazine-M (HO-oxo-) isomer 2.</text></subparagraph> <subparagraph id="H8E3C56698CFE4206B153E795690D0308" commented="no"><enum>(O)</enum><text>Xylazine-M (HO-oxo-) isomer 2 glucuronide.</text></subparagraph>
<subparagraph id="HB9F36FEC5CE648D59491037BF6B9C598" commented="no"><enum>(P)</enum><text>Xylazine-M (sulfone).</text></subparagraph> <subparagraph id="HC0EB840689D9443C88C2D2B337B5B509" commented="no" display-inline="no-display-inline"><enum>(Q)</enum><text>Xylazine-M (sulfone-HO-) isomer 1.</text></subparagraph>
<subparagraph commented="no" display-inline="no-display-inline" id="H42A79293F32A41F28DD91A7EDF3F2A8B"><enum>(R)</enum><text display-inline="yes-display-inline">Any compound, mixture, or preparation which contains any quantity of any of the substances referred to in subparagraphs (A) through (Q).</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection></section> <section id="HC142D1EC047B498CB2E1133411455CEC"><enum>4.</enum><header>Unlawful distribution and penalties relating to xylazine</header> <subsection id="HECCD46F3A43E468B9881285D1CFB30DD"><enum>(a)</enum><header>Prohibited Acts A—Penalties</header> <paragraph commented="no" display-inline="no-display-inline" id="H29302F980CD3450FBD5B697019A9845F"><enum>(1)</enum><header display-inline="yes-display-inline">Controlled Substances Act</header><text>Section 401 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/841">21 U.S.C. 841</external-xref>) is amended—</text>
<subparagraph commented="no" display-inline="no-display-inline" id="HB7F596B4EF0A4C7E8A3B1E2E0E39769A"><enum>(A)</enum><text display-inline="yes-display-inline">in subsection (a)(1), by inserting <quote>or xylazine for illicit uses under section 424</quote> after <quote>controlled substance</quote>; and</text></subparagraph> <subparagraph commented="no" display-inline="no-display-inline" id="H735B54BC858045F9B3EA304E1053490A"><enum>(B)</enum><text>in subsection (b)(1)(E)(i), by inserting <quote>or unlawful distribution of xylazine for illicit uses under section 424</quote> after <quote>schedule III</quote>.</text></subparagraph></paragraph>
<paragraph commented="no" display-inline="no-display-inline" id="H44CC7C43D11447A5AA35CAE0B7559DB0"><enum>(2)</enum><header display-inline="yes-display-inline">Controlled Substances Import and Export Act</header><text>Section 1010 of the Controlled Substances Import and Export Act (<external-xref legal-doc="usc" parsable-cite="usc/21/960">21 U.S.C. 960</external-xref>) is amended—</text> <subparagraph commented="no" display-inline="no-display-inline" id="H1459BFA629D54A48BBA99624B11D5A20"><enum>(A)</enum><text display-inline="yes-display-inline">in subsection (a)—</text>
<clause commented="no" display-inline="no-display-inline" id="H7C618A08CBA744D38543ADE4C3598A8B"><enum>(i)</enum><text display-inline="yes-display-inline">in paragraph (1), by inserting <quote>or xylazine for illicit uses under section 424</quote> after <quote>controlled substance</quote>; </text></clause> <clause commented="no" display-inline="no-display-inline" id="H26611CD5233C4F3EA11BB4C86EA6FCAB"><enum>(ii)</enum><text>in paragraph (2), by inserting <quote>or xylazine for illicit uses under section 424</quote> after <quote>controlled substance</quote>; and</text></clause>
<clause id="H2792F7A287B64A20B32713D8054F3CAC"><enum>(iii)</enum><text>in paragraph (3), by inserting <quote>or xylazine for illicit uses under section 424</quote> after <quote>controlled substance</quote>; and</text></clause></subparagraph> <subparagraph commented="no" display-inline="no-display-inline" id="HD08BBFEA25B440A19E041EDBC1B701DA"><enum>(B)</enum><text>in subsection (b)(5), by inserting <quote>or the unlawful distribution of xylazine for illicit uses under section 424</quote> after <quote>schedule III</quote>. </text></subparagraph></paragraph></subsection>
<subsection id="H6B845A10CAA14AB7A5E897D5D3D941D9"><enum>(b)</enum><header>Illicit use and distribution</header><text>Part D of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/401">21 U.S.C. 401 et seq.</external-xref>) is amended by adding at the end the following:</text> <quoted-block style="OLC" display-inline="no-display-inline" id="HCD906664B28F43048B35E5673E03E380"> <section id="H9F1FA571E8DC47F5BF7E74397CFD933F"><enum>424.</enum><header>Illicit use and distribution of xylazine</header> <subsection id="HAE2799AF9B4845328B84385A3F026869"><enum>(a)</enum><header>Illicit use</header><text display-inline="yes-display-inline">It is unlawful for any person to engage in any of the following illicit uses of xylazine:</text>
<paragraph id="HF6792711EFF049AF956EE6F1BC33AF4D"><enum>(1)</enum><text>Any use in the human species.</text></paragraph> <paragraph id="H8C72C884373A4BC6A0C3CD5DB194A91B"><enum>(2)</enum><text>Any use that is not a licit use.</text></paragraph></subsection>
<subsection id="H59AE4483D6214431A8B54B7A9CCC7C11"><enum>(b)</enum><header>Licit use</header><text display-inline="yes-display-inline">Licit use of xylazine means—</text> <paragraph id="HA4BD8700FFDB4A659F603EBA66DFFAED"><enum>(1)</enum><text>any administration to nonhuman species—</text>
<subparagraph id="H31F9C6640B9D4A3AADC3AB0DCC6D1344" commented="no"><enum>(A)</enum><text>of a drug containing xylazine that has been approved by the Secretary of Health and Human Services under section 512 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360b">21 U.S.C. 360b</external-xref>); or </text></subparagraph> <subparagraph commented="no" display-inline="no-display-inline" id="H1D6979739D7845EAB2D4831812CFB549"><enum>(B)</enum><text display-inline="yes-display-inline">that is permissible under section 512(a)(4) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360b">21 U.S.C. 360b(a)(4)</external-xref>);</text></subparagraph></paragraph>
<paragraph id="H236EA5F75349465A857B27EA3273CD99" commented="no"><enum>(2)</enum><text>the manufacturing, importation, or use of xylazine as an active pharmaceutical ingredient for manufacturing an animal drug approved under section 512 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360b">21 U.S.C. 360b</external-xref>) or issued an investigation use exemption under subsection (j) of such section 512; </text></paragraph> <paragraph id="HD0A6916B6F5542A4B6B5CEDF9F653A25" commented="no"><enum>(3)</enum><text>the manufacturing, importation, or use of a xylazine bulk chemical for pharmaceutical compounding by licensed pharmacists or veterinarians; or</text></paragraph>
<paragraph id="H52E2B37A64A343E2AC463E5F00CA2E6D" commented="no"><enum>(4)</enum><text>another use approved or permissible under the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/301">21 U.S.C. 301 et seq.</external-xref>).</text></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section> <section id="HFB8C132E858C4BF18990B7C70ABC3862"><enum>5.</enum><header>Arcos tracking</header><text display-inline="no-display-inline">Section 307(i) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/827">21 U.S.C. 827</external-xref>) is amended—</text>
<paragraph id="H4E49D77B398449DCBFC8B8D29DC3A23B"><enum>(1)</enum><text display-inline="yes-display-inline">in the matter preceding paragraph (1)—</text> <subparagraph commented="no" display-inline="no-display-inline" id="H237DD3155E2043F696E4D13D8C619644"><enum>(A)</enum><text display-inline="yes-display-inline">by inserting <quote>or xylazine</quote> after <quote>gamma hydroxybutyric acid</quote>;</text></subparagraph>
<subparagraph id="HA5A0E73421CF46B78F2100D5CF02E86B"><enum>(B)</enum><text>by inserting <quote>or 512</quote> after <quote>section 505</quote>; and</text></subparagraph> <subparagraph id="HD1BC7E875E954A90A910519E9B9342DB"><enum>(C)</enum><text>by inserting <quote>respectively,</quote> after <quote>the Federal Food, Drug, and Cosmetic Act,</quote>; and </text></subparagraph></paragraph>
<paragraph id="H86D64342A25F403F9D8AC131BEFBEB57"><enum>(2)</enum><text display-inline="yes-display-inline">in paragraph (6), by inserting <quote>or xylazine</quote> after <quote>gamma hydroxybutyric acid</quote>.</text></paragraph></section> <section id="H0CF6FB1535AC4C61A0A38A588BAC6A8D"><enum>6.</enum><header>Report to Congress on xylazine</header> <subsection id="HE23DC357CABC4A7780413735FF522297"><enum>(a)</enum><header>Initial report</header><text display-inline="yes-display-inline">Not later than 1 year after the date of the enactment of this Act, the Attorney General, acting through the Administrator of the Drug Enforcement Administration and in coordination with the Commissioner of Food and Drugs, shall submit to Congress a report on the prevalence of illicit use of xylazine in the United States and the impacts of such use, including—</text>
<paragraph id="HAFC7A5AF740C4022A9D26E12E3E4AEAD"><enum>(1)</enum><text>where the drug is being diverted;</text></paragraph> <paragraph id="H2BF560C0FCB2498190A3C5B5B31E43D5"><enum>(2)</enum><text>where the drug is originating;</text></paragraph>
<paragraph id="HEFBB6BC01D5844AE86AD704259DAFD72"><enum>(3)</enum><text>whether any analogues to such drug present a substantial risk of abuse;</text></paragraph> <paragraph id="HA8568D1DB4B64059910BD261BCFEFA0C"><enum>(4)</enum><text>whether and to what extent the illicit supply of xylazine derives from the licit supply chain; and</text></paragraph>
<paragraph id="HFDD44DBD7D92405A9695D359E16E31F2"><enum>(5)</enum><text>recommendations for Congress with respect to whether xylazine should be transferred to another schedule under part B of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/811">21 U.S.C. 811 et seq.</external-xref>).</text></paragraph></subsection> <subsection id="HDDBEA7C64A5D4C008854D2F4CF5C94B7"><enum>(b)</enum><header>Additional report</header><text display-inline="yes-display-inline">Not later than 4 years after the date of the enactment of this Act, the Attorney General, acting through the Administrator of the Drug Enforcement Administration and in coordination with the Commissioner of Food and Drugs, shall submit to Congress a report updating Congress on the prevalence of xylazine trafficking, misuse, and proliferation in the United States, including recommendations for Congress with respect to whether xylazine should be transferred to another schedule under part B of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/811">21 U.S.C. 811 et seq.</external-xref>) or removed from schedule III of such part.</text></subsection>
<subsection id="H07D8C88101954ED4912DDA1FDAA52CC3"><enum>(c)</enum><header>Definition</header><text>In this section, the term <term>illicit use</term> means any use described in section 424 of the Controlled Substances Act, as added by section 3 of this Act.</text></subsection></section> <section id="HD476078CCF7D4640A04C34B676DB032A"><enum>7.</enum><header>Declaration of emerging threat</header><text display-inline="no-display-inline">Congress declares illicit xylazine use an emerging drug threat, as defined in section 702 of the Office of National Drug Control Policy Reauthorization Act of 1998 (<external-xref legal-doc="usc" parsable-cite="usc/21/1701">21 U.S.C. 1701</external-xref>), in the United States. </text></section> 
</legis-body></bill>

